NCT06068946 - VK2735 for Weight Management Phase 2 | Biotech Hunter

Enrollment

176

Participants

Timeline

Start Date

August 31, 2023

Primary Completion Date

February 27, 2024

Study Completion Date

April 2, 2024

Conditions

Weight Loss

Interventions

BIOLOGICAL

VK2735

VK2735 is a peptide GLP-1 and GIP dual agonist

BIOLOGICAL

Placebo

Placebo comparator

Trial Locations (20)

32127

Viking Clinical Site #107, Port Orange

32216

Viking Clinical Site #112, Jacksonville

33756

Viking Clinical Site #116, Clearwater

33761

Viking Clinical Site #106, Clearwater

34761

Viking Clinical Site #105, Ocoee

35235

Viking Clinical Site #119, Birmingham

37920

Viking Clinical Site #108, Knoxville

40213

Viking Clinical Site #103, Louisville

46260

Viking Clinical Site #104, Indianapolis

59701

Viking Clinical Site #111, Butte

64131

Viking Clinical Site #102, Kansas City

70072

Viking Clinical Site #109, Marrero

78229

Viking Clinical Site #115, San Antonio

Viking Clinical Site #117, San Antonio

78705

Viking Clinical Site #101, Austin

78731

Viking Clinical Site #118, Austin

85210

Viking Clinical Site #100, Phoenix

90057

Viking Clinical Site #110, Los Angeles

90815

Viking Clinical Site #114, Long Beach

92780

Viking Clinical Site #113, Tustin

All Listed Sponsors

lead

Viking Therapeutics, Inc.

INDUSTRY